---
schema_version: "secwatch.filing_event.v1"
accession: "0001935979-25-000026"
form_type: "8-K"
ticker: "BHVN"
cik: "0001935979"
company_name: "Biohaven Ltd."
filed_at: "2025-04-28T23:59:59+00:00"
generated_at: "2026-05-23T05:15:05.248143+00:00"
event_type: "debt"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Biohaven secures up to $600M non-dilutive financing from Oberland Capital for troriluzole development

## Summary
- First tranche $250M funded at closing on or before April 30, 2025.
- Second tranche up to $150M available upon FDA approval of troriluzole; third tranche up to $200M for acquisitions.
- Oberland receives tiered single-digit royalties on global troriluzole net sales for up to 10 years, capped at multiples.
- Additional milestone payment of 35% of funded amount upon FDA or EMA approval.
- Proceeds to support ongoing clinical trials and commercialization preparations for troriluzole in SCA.

## SEC filing metadata
- accession: 0001935979-25-000026
- form_type: 8-K
- ticker: BHVN
- cik: 0001935979
- company_name: Biohaven Ltd.
- filed_at: 2025-04-28T23:59:59+00:00
- event_type: debt
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 2.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1935979/000193597925000026/0001935979-25-000026-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1935979/000193597925000026/bhvn-20250428.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001935979-25-000026
- JSON: https://secwatch.observer/filing/0001935979-25-000026.json
- Plain text: https://secwatch.observer/filing/0001935979-25-000026.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.